1 / 29

The Relationship between DTCA, Drug Requests and Prescriptions:

The Relationship between DTCA, Drug Requests and Prescriptions: Uncovering Variation across Specialty and Space Stefan Stremersch Joint work with Vardit Landsman and Sriram Venkataraman. Relevance. The patient is ever more informed and requests drugs by brand name

khalil
Download Presentation

The Relationship between DTCA, Drug Requests and Prescriptions:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Relationship between DTCA, Drug Requests and Prescriptions: Uncovering Variation across Specialty and Space Stefan Stremersch Joint work with Vardit Landsman and SriramVenkataraman

  2. Relevance • The patient is ever more informed and requests drugs by brand name • There is great concern that many of these requests are triggered by firms’ DTCA: • Expenses: • $4.4B in US in 2008 • $1.1B in US in 1997 • Patients turn into consumers (Hollon 1999, Camacho, Landsman and Stremersch 2009) • Patient requests are also on the rise in countries that do not allow DTCA (Weiss, et al. 1996)

  3. DTCA – Request – Rx Request DTCA Rx There is controversy in prior literature over the effect of DTCA: • Some studies claim no or a very limited effectof DTCA on brand prescriptions(Calfee, Winston and Stempski 2002; Donohue and Berndt 2004; Manchanda, Xie and Youn 2008; Rosenthal et al. 2003; Zachry et al. 2002) • Other studies raise concerns about the large effect of DTCA on prescriptions for the advertised drug(Bell, Kravitz and Wilkes 1999; ; Iizuka and Jin 2005; Weissman et al. 2004; Wilkes, Bell and Kravitz 2000).

  4. DTCA – Request – RX Request Request DTCA Rx DTCA Rx Most studies on DTCA link it directly to prescriptions and forego the study of drug requests as a mediator, although its mediation is often implied

  5. DTCA – Request – Rx Request DTCA Rx Patient requests for a drug positively affect prescriptions for that drug • 27% of “actors” requesting Paxil also receive a Rx for it(Kravitz et al. 2005) • Up to 2/3 of all requests are fulfilled (Donohue and Berndt 2004; Slaughter and Schumacher 2001) • Patient demand cited as the prime motivation to over-prescribe given scientific profile (Schwartz, Soumerai and Avorn 1989; Camacho, Landsman and Stremersch 2009) Physician heterogeneity is typically not accounted for (Kravitz, et al. 2003&2005; Mintzes et al. 2002&2003), or accounted for with a random effect (Venkataraman and Stremersch 2007)

  6. Why should requests have a positive effect? • Increased satisfaction with a physician visit (Kravitz, et al. 2003) • Increased trust in the physician-patient relationship (Berger, et al. 2001) • Improved perception of the patient that the physician met his or her expectations for care (Bell et al. 2002) • Timegained in medical interviews (Schwartz, Soumerai and Avorn 1989 • Increased patient compliance to the drug regime (Lloyd 1994; Uhlmann et al. 1988).

  7. Relevant Gap in Literature DTCA Request Rx • We know: • Patient requests happen frequently • Patient requests positively affect prescription • Unexplained heterogeneity exists in physicians’ reaction to patient requests • Pharmaceutical companies raise DTCA expenditures • But, we do not know: • Whether brand specific requests are triggered by DTCA • The source of request accommodation heterogeneity across physicians • Whether that source is cause for public concern and/or presents useful information to pharmaceutical managers • Therefore, we question: • Is DTCA affecting the number of drug requests? • Are spatial characteristics and physician specialty possible sources for drug request accommodation heterogeneity?

  8. Specialty Area Demographics Race Income-Education Age Gender Urbanization Our model Request DTCA Rx Request Equation RxEquation Physician characteristic: Direct to physician detailing Spatial characteristics: Competitive Rx’s Lag Rx’s

  9. Model – The Rx equation Request DTCA Rx • Negative Binomial • Log-link function, specifying log of mean of conditional distribution as Heterogeneity in prescription Heterogeneity in responsiveness to requests • Hierarchical formulation: with k = 0, 1

  10. Model – The Request equation Request DTCA Rx • Log-link function (requests) Heterogeneity in the number of requests Heterogeneity in the effect of DTCA on requests Brand-specific periodic shocks, IID MVN, own brand correlation between the shocks of both equations • Hierarchical formulation: Feedback effect

  11. Data We study the statin category in the U.S., June 2002 to July 2003 • We integrate three datasets for our empirical analysis • Physician-level panel data: • Monthly brand-specific prescriptions requests • 5-digit ZIP code • Specialty • Monthly DTCA expenditures (Designated Market Area - DMA) • The 2000 U.S. Census data

  12. Data • Our final dataset contains: • 142,180 prescriptions • For 2,294 physicians • Spanning 1,854 ZIP codes • In 193 DMA’s • Over 14 months

  13. Estimation • Hierarchical Bayes Markov Chain Monte Carlo (HB MCMC) • Gibbs sampling with data augmentation(Tanner and Wong 1987) • Allowing for a combination of random and fixed parameters

  14. Findings: Model Performance

  15. Findings: Parameter Estimates Random Coefficients

  16. 25 out of the 60 seconds of an Eli Lilly & Co. ad Evista were spent on listing risks (blood clots and dying from stroke) Evista http://www.evista.com/pat/index.jsp

  17. Findings: Parameter Estimates Random Coefficients

  18. Findings: second level analysis • Specialists: • Receive more drug requests (δ02=1.06, Std. 0.39) • That are not disproportionally triggered by DTCA (δ11=-0.06, Std. 0.17) • But, such drug requests to specialists translate less into prescriptions than drug requests to primary care physicians (ω11=-0.76, Std. 0.16) • More severe medical condition makes specialists' patients more involved and informed (Gould 1988) • But, their greater intellectual mastery (Kravitz, et al. 2003), may enable specialists to convince patients against the requested drug in a shorter time

  19. Findings: second level analysis • Minorities: • Requests occur more frequently in DMA’s with a higher percentage of Blacks (δ03=3.01, Std. 1.3) and Hispanics (δ04=2.85, Std. 1.03) • The requests in DMA’s with a higher proportion of Blacks are triggeredless by DTCA (δ12=-1.44, Std. 0.58) • Drug requests in DMA’s with a higher proportion of minorities translate less to prescriptions – for Blacks (ω12=-1.1, Std. 0.67), Hispanics (ω13=-1.14, Std. 0.53) and Asians (ω14=-4.47, Std. 2.27)

  20. Findings: second level analysis • Minorities: • Requests occur more frequently in DMA’s with a higher percentage of Blacks (δ03=3.01, Std. 1.3) and Hispanics (δ04=2.85, Std. 1.03) • The requests in DMA’s with a higher proportion of Blacks are triggeredless by DTCA (δ12=-1.44, Std. 0.58) • Drug requests in DMA’s with a higher proportion of minorities translate less to prescriptions – for Blacks (ω12=-1.1, Std. 0.67), Hispanics (ω13=-1.14, Std. 0.53) and Asians (ω14=-4.47, Std. 2.27) Higher reliance on alternative forms of information such as word of mouth among Blacks ( Matthews et al. 2002)

  21. Findings: second level analysis • Minorities: • Requests occur more frequently in DMA’s with a higher percentage of Blacks (δ03=3.01, Std. 1.3) and Hispanics (δ04=2.85, Std. 1.03) • The requests in DMA’s with a higher proportion of Blacks are triggeredless by DTCA (δ12=-1.44, Std. 0.58) • Drug requests in DMA’s with a higher proportion of minorities translate less to prescriptions – for Blacks (ω12=-1.1, Std. 0.67), Hispanics (ω13=-1.14, Std. 0.53) and Asians (ω14=-4.47, Std. 2.27) • Minorities may have difficulties in expressing themselves to physicians(Helman 1994) • Cardiovascular condition of minorities • Fewer physicians in DMA’s with a higher proportion of minorities • Minorities may have more limitations in their insurance policies • Physicians may unintentionally incorporate racial biases in their medical decision-making (Cooper-Patrick, et al. 1999)

  22. Findings: second level analysis • Education and Income: • Does not affect the baseline level of drug requests • Nor the effect of DTCA on drug requests • There is a higher baseline level of prescriptions in DMA’s with higher education and income population (ω05=0.10, Std. 0.04) • But in such DMA’s requests translate less into prescriptions (ω15=0.18, Std. 0.08)

  23. Findings: second level analysis • Education and Income: • Does not affect the baseline level of drug requests • Nor the effect of DTCA on drug requests • There is a higher baseline level of prescriptions in DMA’s with higher education and income population (ω05=0.10, Std. 0.04) • But in such DMA’s requests translate less to prescriptions (ω15=0.18, Std. 0.08) Higher income/education patients manage their health better – statin intake – than lower income/education patients(Cowie and Eberhardt 1995; Langlie 1977)

  24. Findings: second level analysis • Education and Income: • Does not affect the baseline level of drug requests • Nor the effect of DTCA on drug requests • There is a higher baseline level of prescriptions in DMA’s with higher education and income population (ω05=0.10, Std. 0.04) • But in such DMA’s requests translate less to prescriptions (ω15=0.18, Std. 0.08) Educated patients are seen as capable of understanding medical explanations more clearly (Mathews 1983; Roter and Hall 2006; Waitzkin 1985) and this may: • Temper the hazard of dissatisfaction and distrust due to non-accommodation • Allow the physician to change the patient’s mind in the short duration of a visit

  25. Implications • DTCA does not deliver upon the high expectations and should be re-evaluated by manufacturers • Objectives: category size/treatment compliance/firm prices • Content: avoidance of mentioning side effects (FDA) • Drug requests have a large influence: Deserve managerial attention beyond DTCA (E.g. WoM communication between patients or within patient communities) • Our findings should reassure policy makers that DTCA efforts cannot adversely inflate the brand’s edge over competing brands • Our findings may concern policy makers: • The large effect of patient requests (potentially threatening the gate-keeping function of the physician) • Its relation to the demographic make-up of the geographic area (e.g. race!)

  26. Implications We can also graphically depict the spatial patterns we find (-> targeting of marketing efforts to patients by pharmaceutical firms): Request accommodation across DMAs DTCA effect across DMAs

  27. Limitations • We cannot offer any normative claims on whether it is good/bad for a patient when a physician responds favorably to a patient drug request • The aggregation at the DMA level may lead to loss of information, as we do not observe which patients visit which physicians within a DMA (although as DMAs are fairly large, it is unlikely for patients to visit a physician outside their own DMA) • We do not account for patients’ payment mode (health insurance coverage such as Medicaid, Medicare vs. private insurance) – however 97% of our data is on insured patients, and we control for education, income and age • Only one category - statins

More Related